The global congestive heart failure treatment industry is expected to reach $16.5 billion by 2028

company logo

company logo

Global Congestive Heart Failure (CHF) Treatment Devices Market:

Global Congestive Heart Failure (CHF) Treatment Devices Market:

Global Congestive Heart Failure (CHF) Treatment Devices Market:

Dublin, July 5, 2022 (GLOBE NEWSWIRE) — The “Global Congestive Heart Failure Treatment Devices Market Size, Share, and Industry Trend Analysis Report by Product Type, by Regional Outlook and Forecast, 2022 – 2028” report has been added to ResearchAndMarkets.com’s offer.

The global Congestive Heart Failure (CHF) Treatment Devices market size is projected to reach $16.5 Billion by 2028, rising at a market growth rate of 5.4% CAGR during the forecast period.

A heart device is used to keep the heart in a regular rhythm. There are several devices to choose from. An ICD (implantable cardiac defibrillator) is an electrical device that is implanted in the heart. An ICD continuously monitors the heart rhythm and, if it becomes abnormal, delivers a mild shock to the heart muscle (arrhythmia). If a shock is needed, it can be very unpleasant, but it will pass quickly. Instead of a shock, some ICDs use a stimulation system. To restore normal heart rhythm, this type of ICD provides a rapid impulse to the heart muscle. A pacemaker can help the patient avoid sudden cardiac arrest (SCA).

According to the Cleveland Clinic, electrical problems in the ventricles cause delays when they pump/contract in about 30% of people with heart failure. Less oxygen-rich blood is transported to the organs and muscles when the ventricles are not pumping simultaneously. Pump delays worsen heart failure and increase the risk of death from the condition. As part of CRT treatment, a pacemaker is implanted in the patient’s body.

The pacemaker is connected to three wires (leads) that send small electrical impulses to the heart muscle to make the ventricles pump together. A CRT-D is a system that includes the capabilities of a CRT and an ICD. It prevents the ventricles from colliding. The CRT-D delivers a shock to restore normal rhythm if they become out of synch due to ventricular tachycardia or fibrillation. CRT, with or without ICD, improves symptoms in approximately 75% of patients who do not find relief from their symptoms with medication. Cardiac resynchronization therapy improves quality of life, survival, cardiac function and exercise capacity, and reduces the risk of hospitalization.

COVID-19 Impact Analysis

The COVID-19 outbreak is one of the most dangerous pandemics that has largely destroyed the global economy. Several businesses were completely destroyed, while several were badly hit by the arrival of the pandemic. Governments around the world have been forced to impose lockdowns in their countries, temporarily shutting down production units for many goods. In addition, the global supply chain was also disrupted due to strict travel restrictions imposed by governments. This hindered the growth of several industries.

Market growth factors

Increase in the prevalence of heart disease around the world

Failure of the ventricles to pump enough blood to the organs of the body is the initial stage of congestive heart failure. This causes fluid to accumulate in the lungs, liver, abdomen and lower body. The technologies used to treat CHF include pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter-defibrillators (ICDs), and ventricular assist devices. The market for congestive heart failure devices is driven by an increase in cardiovascular disease, technical advances and the number of cardiovascular procedures.

Increasing number of initiatives by government and market parties

One of the major factors driving the growth of the congestive heart failure device market is the increasing number of efforts and initiatives being taken by the government and market players around the world. Governments in different countries have introduced a number of health schemes that a patient can use to treat various diseases and conditions. In addition, congestive heart failure is a very deadly and common condition, becoming the cause of the death of a significant number of people around the world every year. By including CHF in this policy, people can benefit from CHF treatment devices.

Marketing limiting factor:

High cost of these devices

One of the major factors impeding the deployment of congestive heart failure devices is the high cost of installing and operating these devices. There is a significant number of people who suffer from heart conditions and diseases all over the world. Congestive heart failure treatment devices are the most effective and rapid treatment for these conditions. However, people around the world are unable to reap the full benefits of these devices due to their high cost. The cost of implementation of these devices is significantly high due to the composition of several complex and advanced technologies.

Main topics covered:

Chapter 1. Market size and methodology

Chapter 2. Market overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Main factors influencing the market
2.2.1 Market Factors
2.2.2 Market Restrictions

Chapter 3. Competitive Analysis – Global
3.1 KBV cardinal matrix
3.2 Recent industry-wide strategic developments
3.2.1 Partnerships, collaborations and agreements
3.2.2 Product introductions and product extensions
3.2.3 Acquisitions and mergers
3.2.4 Approvals and tests
3.3 Best Winning Strategies
3.3.1 Key Leading Strategies: Percentage Breakdown (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, July – 2022, February) Leading Players

Chapter 4. Global Congestive Heart Failure (CHF) Treatment Devices Market Segment by Type:
4.1 Global Pacemakers Market by Regions:
4.2 Global Implantable Cardioverter Defibrillators Market Analysis by Regions:
4.3 Global Cardiac Resynchronization Therapy Market by Regions:
4.4 Global Ventricular Assist Devices Market Analysis by Regions:

Chapter 5. Global Congestive Heart Failure (CHF) Treatment Devices Market by Regions:

Chapter 6. Company Profiles
6.1 Boston Scientific Corporation
6.1.1 Company overview
6.1.2 Financial analysis
6.1.3 Segmental and regional analysis
6.1.4 Research and development costs
6.1.5 Recent strategies and developments:
6.1.5.1 Approvals and tests:
6.1.5.2 Product Introductions and Product Extensions:
6.1.5.3 Acquisitions and mergers:
6.2 MicroPort Scientific Corporation
6.2.1 Company overview
6.2.2 Financial analysis
6.2.3 Segmental and regional analysis
6.2.4 Research and development costs
6.2.5 Recent strategies and developments:
6.2.5.1 Approvals and tests:
6.2.5.2 Product Introductions and Product Extensions:
6.3 Abbott labs
6.3.1 Company overview
6.3.2 Financial analysis
6.3.3 Segmental and regional analysis
6.3.4 Research and development costs
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, collaborations and agreements:
6.3.5.2 Approvals and tests:
6.3.5.3 Acquisitions and mergers:
6.3.5.4 Product introductions and product extensions:
6.4 Medtronic PLC
6.4.1 Company overview
6.4.2 Financial analysis
6.4.3 Segmental and regional analysis
6.4.4 Research and development costs
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, collaborations and agreements:
6.5 Abiomed, Inc.
6.5.1 Company overview
6.5.2 Financial analysis
6.5.3 Regional analysis
6.5.4 Research and development costs
6.5.5 Recent strategies and developments:
6.5.5.1 Approvals and tests:
6.5.5.2 Acquisitions and Mergers:
6.6 Berlin Heart GmbH
6.6.1 Company overview
6.6.2 Recent strategies and developments:
6.6.2.1 Partnerships, collaborations and agreements:
6.7 Jarvik Heart, Inc.
6.7.1 Company overview
6.8 Lepu Medical Technology (Beijing) Co., Ltd.
6.8.1 Company overview
6.9 BIOTRONIK SE & Co. KG
6.9.1 Company overview
6.9.2 Recent strategies and developments:
6.9.2.1 Partnerships, collaborations and agreements:
6.8.2.2 Approvals and tests:
6.9.2.3 Product Introductions and Product Extensions:
6.10. Osypka Medical GmbH
6.10.1 Company overview

For more information about this report, visit https://www.researchandmarkets.com/r/dqsups

Appendix

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Leave a Comment

Your email address will not be published.